Cancer vaccine being created by UK scientists could stop disease up to 20 years early
Scientists are working to create a new cancer vaccine that could 'detect the undetectable' and stop the disease up to 20 years before it has the chance to develop.
Pharmaceutical giant GSK and the University of Oxford have teamed up to make a vaccine that targets cells at the pre-cancerous stage.
The university has world-leading expertise in the study of pre-cancer biology, such as through identifying and sequencing neoantigens, which are proteins that forms on cancer cells and can be a target for drugs.
Professor Sarah Blagden, who is director of the partnership, said cancer 'does not come from nowhere'.
'You always imagine it would take about a year or two years to develop in your body but, in fact, we now know that cancers can take up to 20 years, sometimes even more, to develop - as a normal cell transitions to become cancerous,' prof Blagden told BBC's Radio 4 on Monday.
'We know that actually at that point, most cancers are invisible when they are going through this, what we now call pre-cancer stage. And so the purpose of the vaccine is not to vaccinate against established cancer, but to actually vaccinate against that pre-cancer stage.'
The GSK-Oxford Cancer Immuno-Prevention Programme has been launched on the back of several technological and scientific advances that have made the potential for vaccines against pre-cancer possible, said prof Blagden.
'We're lucky because there have been a huge amount of technical breakthroughs that mean we can …. start to be able to detect the undetectable,' she said. 'And from that, we've been able to work out what features those cells have as they're transitioning towards cancer, and so we can design a vaccine speficially targeted towards that.'
As part of the deal, GSK will invest up to £50 million over three years into the prgoramme, which will look at how to identify vulnerabilities in pre-cancerous cells with vaccines or targeted medication.
GSK's chief scientific officer Tony Wood said: We're pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists. By exploring precancer biology and building on GSK's expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.'
Currently, more than 385,000 people are diagnosed with cancer each year in the UK, and more than 167,000 people a year will die from it, according to data from Cancer Research UK.
Breast cancer is the UK's most common form of the disease, followed by prostate, lung and bowel cancer, which combined account for nearly half of all cancer deaths.
Science and Technology secretary Peter Kyle said the government would back the life sciences sector to help it deliver research that could transform the health of the country.
'Cancer is a disease that has brought pain and heartbreak to every family in the country, including my own,' he said.
'But through our world-leading universities and businesses working in lockstep, like Oxford and GSK are doing here, we can harness science and innovation to transform what's possible when it comes to diagnosing and treating this disease.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
5 hours ago
- Daily Mail
Good news for gardeners! Scientists have uncovered a simple way to boost plant growth - and all you need is a speaker
Gardeners will try almost anything to help their plants grow. From fancy compost to strict watering times or a regular pruning schedule, there are plenty of ways to give flowers a boost. Some even resort to talking to their plants, convinced they 'respond to vibrations'. But scientists have uncovered a simple way to promote growth – and all you need is a speaker. Experts have found that playing music to plants can make them grow heavier and leafier. However, picking the right playlist is of the utmost importance. A study has found that classical music, such as Bach concertos, boost growth while plants exposed to rock music grow more poorly. 'Playing music to plants is not as crazy as it may sound at first,' Charles Spence, a professor of experimental psychology at the University of Oxford and co-author of the paper, told The Times. The team suggest that a combination of sound frequencies, the tempo of the music and the instruments involved may have the power to stimulate or curb plant growth. For the research, scientists analysed pak choi plants – a type of Chinese cabbage – that were played rock music, classical music or no music at all in bursts throughout the day. The classical selection was Bach's Brandenburg Concertos, considered masterful examples of balance between assorted groups of soloists and a small orchestra. Instrumental rock and metal was used for the other musical group. Everything else that could affect plant growth, such as temperature, humidity and lighting, was strictly controlled and kept the same for all plants in the study. After a six-week study period, the researchers found that the plants played classical music ended up significantly larger, with an average dry weight of 8.99g. Meanwhile those played no music weighed 6.33g on average, while plants played rock music weighed only 3.12g on average. The pak choi that had been exposed to classical music also produced the highest number of leaves, with an average of almost 17 each compared with only 10 leaves for the plants that were played rock. Pak choi Also known as Chinese cabbage, pak choi is a leafy green vegetable. It can be used as baby leaves in salads or as larger rosettes in a stir fry. It can be grown in as little as four weeks. The plant is in season all year round but prefers cool, damp conditions. Analysis of the roots also showed that plants exposed to classical music had the highest total root volume, measuring 90 cubic centimetres – three times more than those played instrumental rock, which reached only 30 cubic centimetres. The plants grown in silence, however, recorded total root volume of 77 cubic centimetres. The team was led by plant scientists and music experts at the University of Malaya in Kuala Lumpur and University Putra Malaysia. They said there was 'promise' around the use of classical music to help stimulate plant growth. 'Classical music may have an effect on plant growth because plants are attuned to vibrations, such as the vibrations of running water in soil, and they react to them biologically,' Professor Spence added. 'Meanwhile the different frequencies in rock music may fall outside the sonic range which boosts plant growth.' He also said that classical music might 'make gardening a more pleasant experience'. Previous studies have also found that plants tend to grow in the direction of soothing music and away from rock music. The findings were published in the journal Evolutionary Studies in Imaginative Culture. The scientists wrote: 'The results reveal that those plants exposed to classical music exhibited significant differences in shoot characteristics with the highest total fresh weight, shoot fresh weight, and mean leaf numbers. 'Meanwhile, those plants exposed to rock music demonstrated values that were the lowest across all plant parameters. 'Despite the promise around the use of classical music to help stimulate plant growth, further studies are undoubtedly still needed before any firm conclusions regarding the potential benefits of exposing plants to an acoustic stimulus can be drawn.'
The Independent
5 hours ago
- The Independent
Vaccine fast-tracked for virus that kills up to 85% of people it infects
A vaccine developed by scientists at the University of Oxford for the deadly Nipah virus may soon be available to patients. The University of Oxford 's vaccine has been granted support from the European Medicines Agency's Prime scheme, which aims to fast track the delivery of treatments to people through closer collaboration with regulators. The World Health Organisation considers Nipah a research priority due to its pandemic potential. The virus is fatal in up to 85% of cases, initially causing symptoms such as fever, headaches, pain, vomiting, and sore throat, but can later lead to fatal brain swelling. Nipah can be transmitted to humans from animals (such as bats or pigs), or contaminated foods and can also be transmitted directly from human to human. The University of Oxford is currently putting its jab for Nipah through phase 1 testing after promising earlier results. It is the first UK academic institution to get access to the Prime scheme from the EMA. Oxford said the additional support offered by Prime "has been granted on the basis of compelling preclinical data and preliminary clinical evidence, and will help to accelerate the development and regulatory approval" of the vaccine. In its letter of confirmation to Oxford investigators, the EMA said: "Nipah virus disease in humans is associated with significant morbidity and a high mortality rate and consequent public health impact. "The increasing frequency of human encounters with fruit bats and spillover into densely populated areas is expanding opportunities for Nipah virus transmission, heightening its outbreak potential." Professor Brian Angus, chief investigator of the Oxford Nipah Vaccine Programme at the Oxford Vaccine Group, said: "This targeted regulatory support for our vaccine programme is a huge boost to the search for a solution to Nipah virus outbreaks. "We are hopeful that the results of these trials will pave the way for us to be able to protect some of the populations most at risk, while also helping the world avoid a future global pandemic." Nipah was first recognised in 1999 during an outbreak among pig farmers in Malaysia. It was also found in Bangladesh in 2001, and nearly annual outbreaks have occurred in that country since. The disease has also occured in eastern India. Evidence of the virus has been found in bat species in a number of countries, including Cambodia, Ghana, Indonesia, Madagascar, the Philippines and Thailand.
Daily Mirror
5 hours ago
- Daily Mirror
Jab update as virus with 'pandemic potential' kills up to 85%
Early symptoms include headaches and fever, but it can get a lot worse A vaccine for the deadly Nipah virus, which has the potential to cause a pandemic, could reach patients sooner thanks to scientists at the University of Oxford. The university's jab for the Nipah virus has received backing from the European Medicines Agency's Prime scheme. This initiative aims to speed up the delivery of treatments to patients by fostering earlier and closer ties with regulators. The World Health Organisation recognises Nipah as a research priority due to its pandemic potential. The virus can be fatal in up to 85% of cases, initially causing symptoms such as fever, headaches, pain, vomiting and a sore throat, but later leading to lethal brain swelling. Nipah can spread to humans from animals like bats or pigs, contaminated food, or directly from human to human. The University of Oxford is currently conducting phase one testing on its Nipah jab following promising early results. It is the first UK academic institution to gain access to the EMA's Prime scheme. Oxford stated that the additional support provided by Prime "has been granted on the basis of compelling preclinical data and preliminary clinical evidence, and will help to accelerate the development and regulatory approval" of the vaccine. In its letter of confirmation to Oxford investigators, the EMA said: "Nipah virus disease in humans is associated with significant morbidity and a high mortality rate and consequent public health impact." Reports are suggesting that the increase in human contact with fruit bats coupled with their incursion into densely populated areas is amplifying the threat of Nipah virus outbreaks. Professor Brian Angus, chief investigator of the Oxford Nipah Vaccine Programme at the Oxford Vaccine Group, welcomed the development, saying: "This targeted regulatory support for our vaccine programme is a huge boost to the search for a solution to Nipah virus outbreaks." He also expressed optimism in vaccine research: "We are hopeful that the results of these trials will pave the way for us to be able to protect some of the populations most at risk, while also helping the world avoid a future global pandemic." First identified during an epidemic among pig farmers in Malaysia in 1999, the Nipah virus has since become an ongoing concern. It was similarly observed in Bangladesh in 2001 and has nefariously reared its head nearly every year since. What's more, traces of this dangerous pathogen have been detected in fruit bat species across various countries, stretching from Cambodia to Thailand.
